Recent news on Mesalazine

Spain's Faes posts healthy increase in profits  -  May 17, 2007
Pharma Times (subscription),...drug Claversal/Asacol/Lixacol (mesalazine), the corticosteroid Dezacor/Rosilan (deflazacort) and the varicose veins treatment Venosmil (hidrosmin).

Inflammatory bowel disease: new treatments won't set market alight  -  Feb 28, 2007
Pharmaceutical Business ReviewLialda's once daily dosage regime is claimed to be a significant step forward for ulcerative colitis treatment over other oral mesalazine and

UK Launch Expands Global Reach of FOSRENOL(R)  -  Mar 5, 2007
CNW Telbec (Communiqués de presse),MEZAVANT(TM) (SPD476) (mesalazine) in Europe, and VYVANSE(TM) (NRP104) (lisdexamfetamine dimesylate) (ADHD), including its scheduling classification by

Zeria, Kyowa Hakko in Japan Co-development and Co-marketing ...  -  Feb 9, 2007
PharmaLive.com (press release),...generic name mesalazine, Asacol is an oral enteric-coated pharmaceutical formulation of mesalazine, a drug for inflammatory bowel disease (IBD).

Fosrenol Launches In UK Today - New Option To Control Phosphate ...  -  Feb 22, 2007
Medical News Today (press release),MEZAVANT™ (SPD476) (mesalazine) in Europe, and VYVANSE™ (NRP104) (lisdexamfetamine dimesylate) (ADHD), including its scheduling classification by the

FOSRENOL(R) Launches in United Kingdom Today  -  Feb 22, 2007
Earthtimes.orgMEZAVANT(TM) (SPD476) (mesalazine) in Europe, andVYVANSE(TM) (NRP104) (lisdexamfetamine dimesylate) (ADHD), including itsscheduling classification by

Shire buys New River Pharmaceuticals for $2.6 billion  -  Feb 21, 2007
Pharma Times (subscription),Looking ahead, Mr Emmens noted that as well as Vyvanse, the company is hoping to launch the ulcerative colitis treatment Lialda/Mezavant (mesalazine) and

FOSRENOL(R) Launches in United Kingdom Today  -  Feb 22, 2007
PR-Inside.com (Pressemitteilung),MEZAVANT(TM) (SPD476) (mesalazine) in Europe, and VYVANSE(TM) (NRP104) (lisdexamfetamine dimesylate) (ADHD), including its scheduling classification by

FDA Approves LIALDA(TM) (mesalamine), the First Oral Once-Daily ...  -  Jan 16, 2007
PR Newswire (press release),MEZAVANT(TM) (SPD476) (mesalazine) in Europe, and VYVANSE(TM) (NRP104) (lisdexamfetamine dimesylate) (ADHD), including its scheduling classification by

Shire Receives Label Agreement in Europe for Ulcerative Colitis ...  -  Dec 14, 2006
PharmaLive.com (press release),Available as a single strength tablet, containing mesalazine 1200mg, Mezavant will be indicated both for the induction of clinical and endoscopic remission

Shire to get European approval for its ulcerative colitis drug  -  Dec 18, 2006
DrugResearcher.com,Although mesalazine is currently used for the condition, if approved, Mezavant would offer a once-daily oral mesalazine treatment for active mild to

Shire edges nearer to European approval for Mezavant  -  Dec 15, 2006
Pharma Times (subscription),The firm noted that core labelling for Mezavant (mesalazine) has been agreed by the regulatory agencies for the 15 European countries participating in the

(PRN) - Shire Receives Label Agreement in Europe for Ulcerative ...  -  Dec 14, 2006
Bolsamania.com,...(PRN) - Shire Receives Label Agreement in Europe for Ulcerative Colitis Treatment, Mezavant(TM) (Mesalazine) ... [+]

Inflammatory bowel disease: next-generation TNF's threat to Remicade  -  Dec 1, 2006
Pharmaceutical Business ReviewIn terms of sales the current IBD market is dominated by Remicade, however, its high price pushes its sales value above those of mesalazine products like

Mezavant MMX Treatment for Ulcerative Colitis Gets Label Agreement ...  -  Dec 19, 2006
PharmaLive.com (press release),Cosmo invented the formulation (the active pharmaceutical ingredient mesalazine is off-patent) and licensed it to Giuliani in 2001 who licensed it further

(PRN) - Canadian Pacific Railway announces 2007 planned capital ...  -  Dec 14, 2006
Bolsamania.com,...(PRN) - Shire Receives Label Agreement in Europe for Ulcerative Colitis Treatment, Mezavant(TM) (Mesalazine) ... [+]. (PRN) - Bowlin Travel Centers Report

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional